Elanco Animal Health Inc., which is headquartered in Indianapolis, has announced a restructuring plan that will eliminate 300 positions across the company and shift another 300 employees to other areas or locations.
According to a press release, Elanco says the organizational changes generate approximately $25 million in savings in 2026 and $60 million in savings in 2027.
Elanco says it is expanding its research and development presence in its new Indianapolis global headquarters and surrounding OneHealth Innovation District, while continuing to invest in its U.S.-based manufacturing footprint. Elanco will further invest in its Kansas monoclonal antibody (mAb) manufacturing facility to support innovation, particularly a major next generation immuno-therapeutic pet innovation…